ArticleJournal of natural products2017
Natural Products Discovered in a High-Throughput Screen Identified as Inhibitors of RGS17 and as Cytostatic and Cytotoxic Agents for Lung and Prostate Cancer Cell Lines.
Open access · greenAbstract read
In one paragraph
Article in Journal of natural products, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
4.7field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Phytochemicals in Inhibition of Prostate Cancer: Evidence from Molecular Mechanisms Studies.Biomolecules · 2022Pooled it
- Function and regulation of RGS family members in solid tumours: a comprehensive review.Cell communication and signaling : CCS · 2023Review
- RGS proteins and their roles in cancer: friend or foe?Cancer cell international · 2023Review
- Fragment-Based Nuclear Magnetic Resonance Screen against a Regulator of G Protein Signaling Identifies a Binding "Hot Spot".Chembiochem : a European journal of chemical biology · 2021Article
- Screening of metabolic modulators identifies new strategies to target metabolic reprogramming in melanoma.Scientific reports · 2021Article
- Molecular Basis of Prostate Cancer and Natural Products as Potential Chemotherapeutic and Chemopreventive Agents.Frontiers in pharmacology · 2021Review
- Unraveling Plant Natural Chemical Diversity for Drug Discovery Purposes.Frontiers in pharmacology · 2020Review
- Regulator of G-protein signaling (RGS) proteins as drug targets: Progress and future potentials.The Journal of biological chemistry · 2019Review
- High-resolution structure of RGS17 suggests a role for CaThe Journal of biological chemistry · 2019Article
- Screen Targeting Lung and Prostate Cancer Oncogene Identifies Novel Inhibitors of RGS17 and Problematic Chemical Substructures.SLAS discovery : advancing life sciences R & D · 2018Article
- Molecular Determinants of Sensitivity or Resistance of Cancer Cells Toward Sanguinarine.Frontiers in pharmacology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Christopher R BodleDepartment of Pharmaceutical Sciences and Experimental Therapeutics, ‡Holden Comprehensive Cancer Center, UIHC, §Cancer Signaling and Experimental Therapeutics Program, Holden Comprehensive Cancer Center, UIHC, ⊥Department of Molecular Physiology and Biophysics, Carver College of Medicine, ∥Department of Molecular Physiology, Biophysics, and Pathology, Holden Comprehensive Cancer Center, Carver College of Medicine, ▽Department of Microbiology, Carver College of Medicine, #Interdisciplinary Graduate Program in Immunology, Carver College of Medicine, University of Iowa , Iowa City, Iowa 52242, United States.ORCID 0000-0001-9581-2447
Duncan I MackieDepartment of Pharmaceutical Sciences and Experimental Therapeutics, ‡Holden Comprehensive Cancer Center, UIHC, §Cancer Signaling and Experimental Therapeutics Program, Holden Comprehensive Cancer Center, UIHC, ⊥Department of Molecular Physiology and Biophysics, Carver College of Medicine, ∥Department of Molecular Physiology, Biophysics, and Pathology, Holden Comprehensive Cancer Center, Carver College of Medicine, ▽Department of Microbiology, Carver College of Medicine, #Interdisciplinary Graduate Program in Immunology, Carver College of Medicine, University of Iowa , Iowa City, Iowa 52242, United States.
Michael P HayesDepartment of Pharmaceutical Sciences and Experimental Therapeutics, ‡Holden Comprehensive Cancer Center, UIHC, §Cancer Signaling and Experimental Therapeutics Program, Holden Comprehensive Cancer Center, UIHC, ⊥Department of Molecular Physiology and Biophysics, Carver College of Medicine, ∥Department of Molecular Physiology, Biophysics, and Pathology, Holden Comprehensive Cancer Center, Carver College of Medicine, ▽Department of Microbiology, Carver College of Medicine, #Interdisciplinary Graduate Program in Immunology, Carver College of Medicine, University of Iowa , Iowa City, Iowa 52242, United States.ORCID 0000-0003-2033-6778
Josephine H SchampDepartment of Pharmaceutical Sciences and Experimental Therapeutics, ‡Holden Comprehensive Cancer Center, UIHC, §Cancer Signaling and Experimental Therapeutics Program, Holden Comprehensive Cancer Center, UIHC, ⊥Department of Molecular Physiology and Biophysics, Carver College of Medicine, ∥Department of Molecular Physiology, Biophysics, and Pathology, Holden Comprehensive Cancer Center, Carver College of Medicine, ▽Department of Microbiology, Carver College of Medicine, #Interdisciplinary Graduate Program in Immunology, Carver College of Medicine, University of Iowa , Iowa City, Iowa 52242, United States.
Michael R MillerDepartment of Pharmaceutical Sciences and Experimental Therapeutics, ‡Holden Comprehensive Cancer Center, UIHC, §Cancer Signaling and Experimental Therapeutics Program, Holden Comprehensive Cancer Center, UIHC, ⊥Department of Molecular Physiology and Biophysics, Carver College of Medicine, ∥Department of Molecular Physiology, Biophysics, and Pathology, Holden Comprehensive Cancer Center, Carver College of Medicine, ▽Department of Microbiology, Carver College of Medicine, #Interdisciplinary Graduate Program in Immunology, Carver College of Medicine, University of Iowa , Iowa City, Iowa 52242, United States.
Michael D HenryDepartment of Pharmaceutical Sciences and Experimental Therapeutics, ‡Holden Comprehensive Cancer Center, UIHC, §Cancer Signaling and Experimental Therapeutics Program, Holden Comprehensive Cancer Center, UIHC, ⊥Department of Molecular Physiology and Biophysics, Carver College of Medicine, ∥Department of Molecular Physiology, Biophysics, and Pathology, Holden Comprehensive Cancer Center, Carver College of Medicine, ▽Department of Microbiology, Carver College of Medicine, #Interdisciplinary Graduate Program in Immunology, Carver College of Medicine, University of Iowa , Iowa City, Iowa 52242, United States.
Jonathan A DoornDepartment of Pharmaceutical Sciences and Experimental Therapeutics, ‡Holden Comprehensive Cancer Center, UIHC, §Cancer Signaling and Experimental Therapeutics Program, Holden Comprehensive Cancer Center, UIHC, ⊥Department of Molecular Physiology and Biophysics, Carver College of Medicine, ∥Department of Molecular Physiology, Biophysics, and Pathology, Holden Comprehensive Cancer Center, Carver College of Medicine, ▽Department of Microbiology, Carver College of Medicine, #Interdisciplinary Graduate Program in Immunology, Carver College of Medicine, University of Iowa , Iowa City, Iowa 52242, United States.
Jon C D HoutmanDepartment of Pharmaceutical Sciences and Experimental Therapeutics, ‡Holden Comprehensive Cancer Center, UIHC, §Cancer Signaling and Experimental Therapeutics Program, Holden Comprehensive Cancer Center, UIHC, ⊥Department of Molecular Physiology and Biophysics, Carver College of Medicine, ∥Department of Molecular Physiology, Biophysics, and Pathology, Holden Comprehensive Cancer Center, Carver College of Medicine, ▽Department of Microbiology, Carver College of Medicine, #Interdisciplinary Graduate Program in Immunology, Carver College of Medicine, University of Iowa , Iowa City, Iowa 52242, United States.
Michael A JamesDepartment of Pharmaceutical Sciences and Experimental Therapeutics, ‡Holden Comprehensive Cancer Center, UIHC, §Cancer Signaling and Experimental Therapeutics Program, Holden Comprehensive Cancer Center, UIHC, ⊥Department of Molecular Physiology and Biophysics, Carver College of Medicine, ∥Department of Molecular Physiology, Biophysics, and Pathology, Holden Comprehensive Cancer Center, Carver College of Medicine, ▽Department of Microbiology, Carver College of Medicine, #Interdisciplinary Graduate Program in Immunology, Carver College of Medicine, University of Iowa , Iowa City, Iowa 52242, United States.
David L RomanDepartment of Pharmaceutical Sciences and Experimental Therapeutics, ‡Holden Comprehensive Cancer Center, UIHC, §Cancer Signaling and Experimental Therapeutics Program, Holden Comprehensive Cancer Center, UIHC, ⊥Department of Molecular Physiology and Biophysics, Carver College of Medicine, ∥Department of Molecular Physiology, Biophysics, and Pathology, Holden Comprehensive Cancer Center, Carver College of Medicine, ▽Department of Microbiology, Carver College of Medicine, #Interdisciplinary Graduate Program in Immunology, Carver College of Medicine, University of Iowa , Iowa City, Iowa 52242, United States.ORCID 0000-0002-8250-0337
Medical College of Wisconsin · US
Funding
Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Christopher K Laubenthal · 2000 to 2026
$70.0MPulmonary Toxicology Facility CoreP30ES005605 · NIEHS · UNIVERSITY OF IOWA · PI Jong Sung Kim · 1990 to 2026
$40.5MMEDICAL SCIENTIST TRAINING PROGRAMT32GM007337 · NIGMS · UNIVERSITY OF IOWA · PI GEYER, PAMELA K., LENTZ, STEVEN R · 1985 to 2020
$15.9MPREDOCTORAL TRAINING PROGRAM IN BIOTECHNOLOGYT32GM008365 · NIGMS · UNIVERSITY OF IOWA · PI KERNS, ROBERT JOHN · 1990 to 2021
$3.8MPredoctoral Training in the Pharmacological SciencesT32GM067795 · NIGMS · UNIVERSITY OF IOWA · PI STRACK, STEFAN · 2004 to 2021
$3.4MCooperative SH2 and SH3 domain-mediated interactions at the adaptor protein Grb2R01CA136729 · NCI · UNIVERSITY OF IOWA · PI HOUTMAN, JON C.D. · 2010 to 2014
$1.6MBiochemical and Cell-Based HTS Assays for RGS17 InhibitorsR01CA160470 · NCI · UNIVERSITY OF IOWA · PI ROMAN, DAVID L. · 2012 to 2014
$888kHigh Throughput Drug Screening RobotS10RR029274 · NCRR · UNIVERSITY OF IOWA · PI RICE, KEVIN G · 2011 to 2011
$730kNCI NIH HHS P30 CA086862NCI NIH HHS R01 CA136729NCI NIH HHS R01 CA160470NCRR NIH HHS S10 RR029274NIEHS NIH HHS P30 ES005605NIGMS NIH HHS T32 GM007337NIGMS NIH HHS T32 GM008365NIGMS NIH HHS T32 GM067795
Abstract
Regulator of G Protein Signaling (RGS) 17 is an overexpressed promoter of cancer survival in lung and prostate tumors, the knockdown of which results in decreased tumor cell proliferation in vitro. Identification of drug-like molecules inhibiting this protein could ameliorate the RGS17's pro-tumorigenic effect. Using high-throughput screening, a chemical library containing natural products was interrogated for inhibition of the RGS17-Gα
Indexed as
BenzophenanthridinesBiological ProductsCytostatic AgentsCytotoxinsGTP-Binding Protein RegulatorsHumansIsoquinolinesLung NeoplasmsMaleMolecular StructurePentacyclic TriterpenesProstatic NeoplasmsTriterpenesBenzophenanthridinesBiological ProductscelastrolCytostatic AgentsCytotoxinsGTP-Binding Protein RegulatorsIsoquinolinesPentacyclic TriterpenessanguinarineTriterpenes
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.